ARTICLE | Clinical News

Competing Hodgkin's presentations at ASH

December 10, 2014 2:59 AM UTC

Shares of Seattle Genetics Inc. (NASDAQ:SGEN) recovered much of their losses, closing up $1.83 to $35.36 on Tuesday after dipping $2.57 to $33.53 on Monday amid competitive presentations in Hodgkin's lymphoma at the American Society of Hematology meeting in San Francisco.

Bristol-Myers Squibb Co. (NYSE:BMY) and Merck & Co. Inc. (NYSE:MRK) presented Phase I data from their respective programmed cell death 1 ( PDCD1; PD-1; CD279) compounds in the indication, both of which enrolled patients who had relapsed on or after treatment with Adcetris brentuximab from Seattle Genetics. The antibody-drug conjugate (ADC) has accelerated approval in the U.S. for Hodgkin's lymphoma in patients who are at risk of relapse after autologous stem cell transplant (ASCT) or prior chemotherapy. ...